AMBS — Amarantus Bioscience Holdings Cashflow Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $38.83m
Annual cashflow statement for Amarantus Bioscience Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2013 December 31st | 2014 December 31st | 2015 December 31st | 2017 December 31st | 2018 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15.1 | -27.3 | -25.2 | -4.63 | -10.6 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 10.9 | 10.5 | 10.1 | 0.491 | 10.1 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.737 | 5.29 | -1.11 | 9.03 | 15.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -3.47 | -11.3 | -16 | 4.89 | 14.9 |
| Capital Expenditures | 0 | -0.231 | -0.01 | 0 | -0.003 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.07 | -1.3 | -4.9 | — | — |
| Acquisition of Business | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.07 | -1.53 | -4.91 | 0 | -0.003 |
| Financing Cash Flow Items | -0.325 | -0.043 | -0.293 | 1.76 | 2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.42 | 12 | 20.9 | 0.849 | -4.33 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.875 | -0.819 | -0.038 | 5.74 | 10.5 |